TNF and non-small cell lung carcinoma: In our study, it was confirmed that the therapeutic agents for RA, the TNF inhibitors ADALIMUMAB, GOLIMUMAB, ETANERCEPT, CERTOLIZUMAB PEGOL, and INFLIXIMAB, increase the risk of NSCLC, a finding that provides an important addition to the existing studies on the association between RA and NSCLC.